Tardive Dyskinesia
📧 Sign up to get email alerts when something new happens for Tardive Dyskinesia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia [Phase 2]
A Phase 2 clinical trial evaluating the efficacy, safety, and tolerability of NBI-1065890 versus placebo in adults with tardive dyskinesia.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor [Phase 4]
Phase 4 trial evaluating valbenazine for tardive dyskinesia in adults who remain symptomatic on or after VMAT2 inhibitor treatment; recruitm…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities [Phase 4]
This is a Phase 4 clinical trial update for deutetrabenazine targeting tardive dyskinesia in individuals with intellectual or developmental …
-
FDA label_change · 2026-04-08FDA Approved: INGREZZA SPRINKLE — Supplemental Application (Neurocrine Biosciences, Inc.)
FDA approved a supplemental application to add INGREZZA SPRINKLE (valbenazine) as a sprinkle formulation for tardive dyskinesia, including u…
-
EMA approval · 2026-01-23EMA Authorised: Austedo (deutetrabenazine) — Teva GmbH
The European Medicines Agency authorised Austedo (deutetrabenazine) for the treatment of tardive dyskinesia, with Teva GmbH as the marketing…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-16Clinical Trial Update: Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia [Phase 4]
Phase 4 study evaluating valbenazine for tardive dyskinesia in participants with schizophrenia, schizoaffective disorder, bipolar disorder, …
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD [NA]
A single-center, double-blind, randomized, placebo-controlled trial is evaluating the efficacy and safety of precise localization rTMS for r…
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: Xenazine in Late Dyskinetic Syndrome With Neuroleptics [Phase 3]
Phase 3 trial update on Xenazine (tetrabenazine) for tardive dyskinesia in patients treated with neuroleptics; the study has completed.
-
CLINICAL_TRIALS withdrawal · 2025-07-11Clinical Trial Update: Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine [Phase 1]
The Phase 1 clinical trial evaluating reduction of demoralization in patients with tardive dyskinesia after treatment with valbenazine has b…
-
CLINICAL_TRIALS research · 2025-05-01Clinical Trial Update: ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders [NA]
Clinical trial update on ExAblate Transcranial MRgFUS for treatment-refractory movement disorders; the study is currently active but not rec…
-
FDA approval · 2025-02-28FDA Approved: AUSTEDO XR — Supplemental Application (Teva Neuroscience, Inc.)
FDA approved a supplemental application for AUSTEDO XR (deutetrabenazine) from Teva Neuroscience, Inc. The action involves the extended-rele…
-
FDA approval · 2025-02-28FDA Approved: AUSTEDO — Supplemental Application (Teva Neuroscience, Inc.)
FDA approved a supplemental application for Austedo (deutetrabenazine) from Teva Neuroscience, Inc. The approval updates the labeling for th…
-
CLINICAL_TRIALS research · 2025-01-22Clinical Trial Update: Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia [Phase 1, Phase 2]
This clinical trial update describes ongoing Phase 1/Phase 2 studies evaluating the safety and efficacy of LPM3770164 sustained-release tabl…
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects [Phase 1]
Phase 1 study assessing safety, tolerability and pharmacokinetics of escalating doses of LPM3770164 in healthy subjects, with potential rele…
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets [Phase 1]
A Phase 1 clinical trial evaluating the effect of food on the pharmacokinetics of LPM3770164 sustained-release tablets. The study is complet…
-
FDA label_change · 2024-11-26FDA Approved: AUSTEDO — Supplemental Application (Teva Neuroscience, Inc.)
FDA approved a supplemental application for AUSTEDO (deutetrabenazine) from Teva Neuroscience, Inc., updating the product labeling.
-
FDA approval · 2024-11-22FDA Approved: INGREZZA — Supplemental Application (Neurocrine Biosciences, Inc.)
The FDA approved a supplemental application for INGREZZA (valbenazine) from Neurocrine Biosciences, Inc., resulting in an updated label for …
-
CLINICAL_TRIALS withdrawal · 2024-10-24Clinical Trial Update: Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities [Phase 4]
Phase 4 trial of valbenazine for tardive dyskinesia in adults with intellectual/developmental disabilities has been withdrawn.
-
FDA approval · 2024-07-01FDA Approved: AUSTEDO XR — Supplemental Application (Teva Neuroscience, Inc.)
The FDA approved Teva's supplemental application for AUSTEDO XR (deutetrabenazine), an extended-release formulation of Austedo.
-
FDA approval · 2024-05-29FDA Approved: AUSTEDO XR — Supplemental Application (Teva Neuroscience, Inc.)
FDA approved a supplemental application for AUSTEDO XR (deutetrabenazine) by Teva Neuroscience, expanding the product to include an extended…
-
FDA approval · 2024-04-30FDA Approved: INGREZZA SPRINKLE — Original Application (Neurocrine Biosciences, Inc.)
FDA approves INGREZZA SPRINKLE (valbenazine) via an original application for the treatment of tardive dyskinesia.
-
FDA approval · 2023-09-28FDA Approved: AUSTEDO — Supplemental Application (Teva Neuroscience, Inc.)
FDA approved a supplemental application for Austedo (deutetrabenazine) submitted by Teva Neuroscience, Inc. The approval updates the labelin…
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia [Phase 2, Phase 3]
Phase 2 and Phase 3 trials evaluated MT-5199 for efficacy and safety in tardive dyskinesia. Results have been posted.
-
FDA approval · 2023-02-17FDA Approved: AUSTEDO XR — Original Application (Teva Neuroscience, Inc.)
FDA approved AUSTEDO XR (deutetrabenazine) from Teva Neuroscience in an original NDA; the extended-release formulation targets symptoms of H…
-
FDA approval · 2022-08-11FDA Approved: INGREZZA — Supplemental Application (Neurocrine Biosciences, Inc.)
FDA approved a supplemental application for Ingrezza (valbenazine) from Neurocrine Biosciences. The approval expands the drug's labeling.